Janssen ’s BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma

RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson& Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-4528, an...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials